Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Related Questions
What were the size, direction (buy or sell), and timing of the insider transactions disclosed?
Do the insiders' actions suggest confidence or concern about Novo Nordisk's near‑term outlook, and how might that influence market sentiment?
How could this insider activity impact short‑term price volatility and liquidity, and should it affect our trading strategy or position sizing?